Frankfurt - Terumo Corporation has reached an agreement with WuXi Biologics for Terumo to acquire the drug product (DP) plant in Leverkusen, Germany, together with the quality control laboratory in Wuppertal (Aprath), for 150 million euros (approximately 24.6 billion yen).
Terumo operates in the Contract Development and Manufacturing Organization (CDMO) sector, a business model that offers comprehensive development and production services for pharmaceutical and medical products, from concept to market launch.
The DP plant acquired from WuXi Biologics is equipped with state-of-the-art facilities compliant with GMP standards and boasts highly skilled personnel, production expertise and a proven track record. By setting up a new CDMO production base in Europe, Terumo intends to expand its production capacity, bolster its global operations and fulfil the increasing requirements of pharmaceutical companies, both at home and abroad.
A CMS team led by lead partner Dr. Hendrik Hirsch provided comprehensive legal advice to Terumo on the transaction, including regulatory, IP and labor advice.
Press Contact
presse@cms-hs.com
